A Customized Pigmentation SNP Array Identifies a Novel SNP Associated with Melanoma Predisposition in the \( SLC45A2 \) Gene

Maider Ibarrola-Villava\(^1\),\(^2\)\(^3\), Lara P. Fernandez\(^2\)\(^3\), Santos Alonso\(^3\), M. Dolores Boyano\(^4\), Maria Peña-Chilet\(^1\), Guillermo Pita\(^2\), Jose A. Aviles\(^5\), Matias Mayor\(^6\), Cristina Gomez-Fernandez\(^6\), Beatriz Casado\(^6\), Manuel Martin-Gonzalez\(^7\), Neskuts Izagirre\(^3\), Concepcion De la Rua\(^3\), Aintzane Asumendi\(^4\), Gorka Perez-Yarza\(^9\), Yoana Arroyo-Berdugo\(^4\), Enrique Boldo\(^8\), Rafael Lozoya\(^9\), Arantxa Torrijos-Aguilar\(^9\), Ana Pitarch\(^10\), Gerard Pitarch\(^10\), Jose M. Sanchez-Motilla\(^10\), Francisca Valcuende-Caverlo\(^10\), Gloria Tomas-Cabedo\(^11\), Gemma Perez-Pastor\(^11\), Jose L. Diaz-Perez\(^12\), Jesus Gardeazabal\(^13\), Inigo Martinez de Lizarduy\(^13\), Ana Sanchez-Diez\(^13\), Carlos Valdes\(^13\), Angel Pizarro\(^6\), Mariano Casado\(^6\), Gregorio Carretero\(^14\), Rafael Botella-Estrada\(^15\), Eduardo Nagore\(^15\), Pablo Lazaro\(^5\), Ana Lluch\(^1\), Javier Benitez\(^2\), Conrado Martinez-Cadenas\(^16\)\(^a\), Gloria Ribas\(^1\)\(^2\)\(^b\)

\(^1\) Servicio de Oncologia Medica y Hematologia, Fundacion Hospital Clinico Universitario-INCLIVA, Valencia, Spain, \(^2\) Programa Genetica Humana, CNIO, Madrid, Spain, \(^3\) Departamento de Genetica, Antropologia Fisica y Fisiologia Animal, Universidad del Pais Vasco, Leioa, Spain, \(^4\) Departamento de Biologia Celular e Histologia, Universidad del Pais Vasco, Leioa, Spain, \(^5\) Departamento de Dermatologia, Hospital Gregorio Maranon, Madrid, Spain, \(^6\) Departamento de Dermatologia, Hospital La Paz, Madrid, Spain, \(^7\) Departamento de Dermatologia, Hospital Ramon y Cajal, Madrid, Spain, \(^8\) Unidad de Cirugia Oncologica, Hospital Provincial Castellon, Castellon, Spain, \(^9\) Servicio de Dermatologia, Hospital Provincial Castellon, Castellon, Spain, \(^10\) Servicio de Dermatologia, Hospital General Castellon, Castellon, Spain, \(^11\) Servicio de Dermatologia, Hospital La Plana, Vila-real, Castellon, Spain, \(^12\) Servicio de Dermatologia, Hospital de Cruces, Baracaldo, Spain, \(^13\) Servicio de Dermatologia, Hospital de Basurto, Bilbao, Spain, \(^14\) Department of Dermatology, Hospital Dr Negrin, Las Palmas de Gran Canaria, Spain, \(^15\) Instituto Valenciano de Oncologia, Valencia, Spain, \(^16\) Laboratorio de Biopatologia Molecular, Hospital Provincial Castellon, Castellon, Spain

Abstract

As the incidence of Malignant Melanoma (MM) reflects an interaction between skin colour and UV exposure, variations in genes implicated in pigmentation and tanning response to UV may be associated with susceptibility to MM. In this study, 363 SNPs in 65 gene regions belonging to the pigmentation pathway have been successfully genotyped using a SNP array. Five hundred and ninety MM cases and 507 controls were analyzed in a discovery phase I. Ten candidate SNPs based on a \( p \)-value threshold of 0.01 were identified. Two of them, rs35414 (\( SLC45A2 \)) and rs2069398 (\( SILV/CDK2 \)), were statistically significant after conservative Bonferroni correction. The best six SNPs were further tested in an independent Spanish series (624 MM cases and 789 controls). A novel SNP located on the \( SLC45A2 \) gene (rs35414) was found to be significantly associated with melanoma in both phase I and phase II (\( P < 0.0001 \)). None of the other five SNPs were replicated in this second phase of the study. However, three SNPs in \( TYR, SILV/CDK2 \) and \( ADAMTS20 \) genes (rs17793678, rs2069398 and rs1510521 respectively) had an overall \( p \)-value of 0.05 when considering the whole DNA collection (1214 MM cases and 1296 controls). Both the \( SLC45A2 \) and the \( SILV/CDK2 \) variants behave as protective alleles, while the \( TYR \) and \( ADAMTS20 \) variants seem to function as risk alleles. Cumulative effects were detected when these four variants were considered together. Furthermore, individuals carrying two or more mutations in \( MC1R \), a well-known low penetrance melanoma-predisposing gene, had a decreased MM risk if concurrently bearing the \( SLC45A2 \) protective variant. To our knowledge, this is the largest study on Spanish sporadic MM cases to date.

Citation: Ibarrola-Villava M, Fernandez LP, Alonso S, Boyano MD, Peña-Chilet M, et al. (2011) A Customized Pigmentation SNP Array Identifies a Novel SNP Associated with Melanoma Predisposition in the \( SLC45A2 \) Gene. PLoS ONE 6(4): e19271. doi:10.1371/journal.pone.0019271

Editor: Francesc Palau, Instituto de Ciencia de Materiales de Madrid - Instituto de Biomedicina de Valencia, Spain

Received December 22, 2010; Accepted March 25, 2011; Published April 29, 2011

Copyright: © 2011 Ibarrola-Villava et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by grants from the Ministerio de Educacion y Ciencia (MEC) [SAF2007-65542-C02-01, SAF2009_07072E; BES-2008-009234 to M.I.V. and CP08-0069 “Miquel Servet SNS Contract” to G.R.]; Ministerio de Ciencia e Innovacion [CGL2008-04066/BOS]; Network RD06-0020-1060; the Fundacion Mutua Madrileña and the Fundacion Hospital Provincial de Castellon, Spain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

a E-mail: martinezconrado@yahoo.es
b These authors contributed equally to this work.
c Current address: Servicio de Oncologia Medica y Hematologia, Fundacion Investigacion Hospital Clinico-INCLIVA, Valencia, Spain
Introduction

Malignant melanoma (MM) is a cancer of melanocytes (pigment-producing cells) located predominantly along the basal layer of the epidermis, but also found in mucous membranes. The most relevant epidemiologic characteristic of MM is its increasing incidence among Caucasian populations [1]. The aetiology of MM remains unclear but it is known that both genetic and environmental factors influence the development of sporadic disease [2].

If putative genetic pathways involved in MM susceptibility are considered, the human pigmentation pathway seems to have a main role in the pathogenesis of the disease. MM predisposition is highest in fair skin, high mole count, blond or red-haired individuals who never tan and always burn (Fitzpatrick's phototypes I and II) [2]. Since the incidence of MM reflects an interaction between skin colour and UV exposure, variations in genes implicated in pigmentation and tanning response to UV may be associated with susceptibility to MM and may be useful predictors of MM risk in the general population [3–6].

In recent years, considerable effort has been devoted to understanding the role of low penetrance genes in the pathogenesis of cancer. Linkage analysis in families affected with cancer has led to the identification of highly penetrant MM cancer genes: \textit{CDKN2A} (MIM\#107530, KITLG (MIM\#611664), \textit{TTR} (MIM\#606933), \textit{OC12}/\textit{HERC2} (MIM\#605837), \textit{MC1R} (MIM\#135555) or \textit{SLC45A2} (MIM\#606202) genes [14,19–21] seem to be involved in pigmentation and/or MM susceptibility.

Considering the involvement of pigmentation in MM predisposition, we investigated the role of 384 polymorphisms in 65 pigmentation gene regions in MM susceptibility using two large independent series of Spanish samples (1214 MM cases and 1296 controls in total). To our knowledge, this is the largest study on Spanish sporadic MM cases to date.

Results

From the initial list of 384 variants, 21 SNPs (5.4%) were discarded due to failed genotyping (no PCR amplification, insufficient intensity for cluster separation or poor cluster definition). Overall, 363 SNPs were studied, representing all initially selected genes. Evidence of departure from HWE among controls was observed for ten SNPs, although none of them remained statistically significant after a conservative Bonferroni correction for multiple testing. The number of SNPs successfully genotyped in each gene in discovery phase I is included in Table S1. Their genomic positions are summarized as follows: 256 intronic (66.7%), 47 5′ UTR upstream (12.5%), 64 3′ UTR downstream (16.7%) and 16 coding (4.2%).

Comparison of allele frequencies

Estimated allele frequencies for all 363 SNPs based on the Spanish sample are provided in Table S1. We compared our Spanish frequencies to those of HapMap CEU subjects, using the HapMap minor allele as the reference (Figure 1). Frequencies were very similar, with a high positive correlation (R²) of 0.85. For 20 SNPs (5.5%), the minor allele reported in HapMap was found to be the most frequent allele in the Spanish sample (values above the dotted horizontal line in Figure 1). For 143 of the 363 SNPs considered (39%), one-sample t-test gave evidence that the corresponding Spanish minor allele frequency (MAF) differed from that published in HapMap (p<0.05) (shown in dark grey in Figure 1). However, when the Bonferroni correction was applied.

![Figure 1. Comparison of minor allele frequencies, Spanish versus HapMap European data.](https://example.com/image.png)

Black dots represent values that significantly differ from HapMap European data, when sample size was considered (not corrected by Bonferroni method).

doi:10.1371/journal.pone.0019271.g001
Associations with MM risk

Representation of $-\log_{10}$ p-values for the comparison of MAFs between the 590 Spanish MM cases and the 507 controls are detailed in Figure 2. Considering a p-value threshold of 0.05, 30 SNPs located in 18 genes on eleven individual chromosomes were associated with MM in the Spanish population. Detailed information on rs number, genes, chromosome location, MAFs, OR, 95% CI and p-values for comparisons between cases and control subjects are represented in Table S2. However, if a more restrictive p-value threshold of 0.01 is established, only ten SNPs, located in six genes (one in each of ADAMTS20, TYR and SILV-CDK2; two in each of KIT and MYO7A; and three in SLC45A2) on six individual chromosomes constituted the top ten MM associated SNPs in our Spanish population. Among them, two SNPs (rs35414 and rs2069398), located in two different genes (SLC45A2 and SILV-CDK2 respectively), are statistically significant after applying the Bonferroni correction for multiple comparisons (p-value = 0.0001). Results, including SNP chromosome and gene region, allele frequencies of the top ten MM-associated SNPs, p-values from comparisons between cases and controls and p-values for Bonferroni correction are summarized in Table 1.

From these ten associated SNPs, the one with the best p-value in each gene (six SNPs) was chosen to be studied in validation phase II, consisting on an independent Spanish set of 624 MM cases and 789 controls. The concordance rate between duplicate samples in the quality control analysis was 100%. None of the SNPs presented evidence of departure from HWE. One SNP, rs35414 in SLC45A2 gene, had an unadjusted p-value = 0.002 in phase II and an overall p-value, 0.0001 with an overall OR = 0.75 (95% CI 0.67–0.84) (Figure 3). None of the other five SNPs tested in phase II reached statistical significance at this stage. However, three of them, located in TYR, SILV-CDK2 and ADAMTS20 had an overall p-value<0.05 when phase I and II were considered together.

Table 1. Top ten SNPs associated with Malignant Melanoma p<0.01.

| Gene            | Chr | SNP       | Allele | Ma/M | MAF Cases | MAF Controls | OR (95% CI) | p-value | p-B |
|-----------------|-----|-----------|--------|------|-----------|--------------|-------------|---------|-----|
| KIT             | 4   | rs759083  | C/G    | 0.40 | 0.34      | 1.26 (1.06–1.50) | 0.009      |         |     |
|                 |     | rs13135792| T/C    | 0.38 | 0.33      | 1.27 (1.07–1.52) | 0.0071     |         |     |
| SLC45A2         | 5   | rs35405   | C/T    | 0.48 | 0.42      | 1.26 (1.06–1.49) | 0.0084     |         |     |
|                 |     | rs35414   | C/T    | 0.37 | 0.45      | 0.71 (0.60–0.84) | 0.0001     | 0.04   |     |
|                 |     | rs35415   | C/A    | 0.39 | 0.47      | 0.73 (0.62–0.87) | 0.0004     | 0.14   |     |
| MYO7A           | 11  | rs948970  | C/G    | 0.44 | 0.49      | 0.80 (0.68–0.94) | 0.0098     |         |     |
|                 |     | rs3758708 | G/A    | 0.13 | 0.08      | 1.63 (1.20–2.22) | 0.0016     | 0.58   |     |
| TYR             | 11  | rs17793678| C/T    | 0.28 | 0.23      | 1.32 (1.09–1.60) | 0.0049     |         |     |
| ADAMTS20        | 12  | rs1510521 | T/C    | 0.37 | 0.31      | 1.30 (1.09–1.55) | 0.0039     |         |     |
| SILV-CDK2       | 12  | rs2069398 | G/A    | 0.06 | 0.10      | 0.52 (0.38–0.72) | 0.0001     | 0.04   |     |

Ma, Major; Mi, Minor; MAF, minor allele frequency; OR, odds ratio per minor allele; CI, confidence interval; B, Bonferroni. Bold indicates statistically significant results.

doi:10.1371/journal.pone.0019271.t001
Three or four rare alleles, rs35414 T/T and rs2069390 A/-, were associated with melanoma risk predisposition. Dots represent odds ratios in the treated sub-groups versus those in control groups. Diamond shapes represent pooled results for each phase, discovery (phase I) and validation (phase II). Squares represent the overall odds ratios. The size of the square is proportional to the number of individuals, and error bars represent 95% confidence intervals.

doi:10.1371/journal.pone.0019271.g003

(1214 MM cases and 1296 controls). These three SNPs were: rs17793678 in an intronic region of the TYR gene with an overall OR = 1.22 (95% CI 1.07–1.34, p-value = 0.003); rs2069398 located in exon 1 of the CDK2 gene and a putative promoter region of the SLY gene, with an overall OR = 0.73 (95% CI 0.58–0.90, p-value = 0.004); and rs1510521 in an ADAMTS29 intron with an overall OR = 1.13 (95% CI 1.01–1.27, p-value = 0.048). A fourth SNP, rs3758708 in the MYO7A gene, was marginally associated with MM (OR = 1.18, 95% CI 0.98–1.41, p-value = 0.09).

We observed some degree of epistatic protective interaction between rs35414 (SLC45A2 gene) and rs2069398 (SLY-CDK2 gene region) when considering rare allele carriers at both loci. Results including joint genotypes (rs35414 and rs2069398), status of individuals (controls or cases), total number of samples, ORs (95% CI) and p-values are shown in Table 2a. We observed a significant decrease in OR when two or three of the rare alleles were present at both loci, rs35414 C/T and rs2069398 A/-, OR 0.54 (95% CI 0.39–0.75) p-value = 0.0003, and when three or four rare alleles, rs35414 T/T and rs2069390 A/-, were present we obtained and OR = 0.31 (95% CI 0.18–0.55) with p-value = 0.0001.

Furthermore, some degree of epistatic risk interaction was also seen between rs17793678 (TYR) and rs1510521 (ADAMTS29) when considering rare alleles at both loci. Results including joint genotypes (rs17793678 and rs1510521), status of individuals (controls or cases), total number of samples, ORs (95% CI) and p-values are shown in Table 2b. We observed a risk effect when two or three rare alleles were present at both loci, rs17793678 C/T and rs1510521 G/-, OR 1.54 (95% CI 1.12–1.78) p-value = 0.004, and when three or four rare alleles, rs17793678 T/T and rs1510521 G/-, were present we obtained an OR = 1.54 (95% CI 0.96–2.48) with a trend toward significance (p-value = 0.088).

The role of SLC45A2 in melanoma predisposition was further analyzed in relation to MC1R, the main low penetrance gene associated to melanoma. Since both genes have been studied by the published HapMap MAFs should probably not be taken as significant after multiple testing (Bonferroni correction). Although the ADAMTS29 gene was associated with light eye colour (p = 0.0339), blond or red hair colour (p = 0.0533) and with number of naevi <50 (rs1510521; p = 0.0338); Finally, SLY-CDK2 SNP rs2069398 was associated with absence of childhood sunburns (p = 0.0333). Table S3 summarizes results for eye, skin and hair colour, presence of childhood sunburns, number of naevi and the presence of solar lentigines. Results in bold represent those with associated p-values<0.05.

**Haplotypes structure at the SLC45A2 locus with reported associations with MM**

The SLC45A2 gene haplotype structure (obtained using HapMap data) is shown in Figure S1. This locus, located in chromosome 5, is represented by two main haploblocks, one located at the 3’ end of the gene (2 kb), and another one comprising the 5’ end of the gene (13 kb), which includes part of intron 1 and the closest putative promoter. SNPs located between these two LD blocks are not defined in any additional block structure, probably due to their low minor allele frequencies.

**Discussion**

In this study, 363 tag SNPs in 65 pigmentation-related gene regions were successfully genotyped in 590 MM cases and 507 controls in discovery phase I. In addition, 624 MM cases and 789 controls were genotyped for the top six MM-associated SNPs in validation phase II. Thus, a total of 1214 MM cases and 1296 controls have been evaluated in this study. Among 363 SNPs in 65 pigmentation gene regions, allele frequencies were highly correlated between the HapMap (CEU) and the Spanish samples (R2 = 0.85). Despite of 143 SNPs with minor allele frequencies different from those published in HapMap, none remained significant after multiple testing (Bonferroni correction). Although the published HapMap MAFs should probably not be taken as definitive [at least for a Southern European population], overall, the HapMap CEU sample is representative of the Spanish population. Therefore, the HapMap data can be used in assessing the appropriateness of SNPs for inclusion in association studies.
even though we are analyzing genes with putative phenotypic implications.

From discovery phase I, p-values below 0.05 were obtained for 30 SNPs and, of these, ten final candidate SNPs, based on an arbitrary p-value threshold of 0.01, were identified. We were encouraged to follow a validation phase due to two SNPs (rs35414 and rs2069398) remaining statistically significant after Bonferroni correction. After testing six of these ten SNPs in an independent Spanish series with 624 MM cases and 789 controls, one SNP (rs35414) on an intronic region of the SLC45A2 gene significantly associated with melanoma was confirmed (p, 0.0001). Three additional SNPs in TYR, SILV/CDK2 and ADAMTS20 (rs17793678, rs2069398 and rs1510521 respectively) had an overall p-value, 0.05 when considering the whole data set (1214 MM cases and 1296 controls). However, in validation phase II, data for these three SNPs did not reach statistical significant results per se.

Recent GWAS have unveiled association between SNPs or genetic variants in MC1R, TPCN2, ASIP, KITLG, SLC24A5, TYR, IRF4, OCA2/HERC2, SLC24A4, SLC45A2, TYRP1, and pigmentation as well as melanoma. These findings emphasize the contribution of pigmentation to melanoma predisposition and tumourigenesis through gene-environment interactions [19–21,25].

The top predisposing MM-associated gene in our study has functions related to melanosomal formation, maturation and transportation. The SLC45A2 gene (MIM #606202) encodes a protein that acts, presumably, as a membrane-associated trans-

**Table 2.** Interactions between protective (a) and risk (b) variants and their effect on MM susceptibility.

| Joint genotype | Spanish population | Cases | Controls | N | OR (95%CI) | p-value |
|----------------|---------------------|-------|----------|---|------------|---------|
| rs35414 (SLC45A2) | rs2069398 (SILV) |       |          |   |            |         |
| C/C G/G          |                     | 431   | 340      | 771| 1          | REF     |
| A/-              |                     | 54    | 57       | 111| 0.75 (0.50–1.11) | 0.15   |
| C/T G/G          |                     | 485   | 538      | 1023| 0.71 (0.59–0.86) | 0.0004 |
| A/-              |                     | 70    | 103      | 173| 0.54 (0.39–0.75) | 0.0003 |
| T/T G/G          |                     | 149   | 199      | 348| 0.59 (0.46–0.76) | 0.0001 |
| A/-              |                     | 17    | 43       | 60 | 0.31 (0.18–0.55) | 0.0001 |
| rs17793678 (TYR) | rs1510521 (ADAMTS20) |       |          |   |            |         |
| C/C A/A          |                     | 297   | 371      | 668| 1          | REF     |
| G/-              |                     | 361   | 382      | 743| 1.18 (0.96–1.46) | 0.122  |
| C/T A/A          |                     | 203   | 224      | 427| 1.13 (0.89–1.44) | 0.321  |
| G/-              |                     | 260   | 230      | 490| 1.41 (1.12–1.78) | 0.004  |
| T/T A/A          |                     | 40    | 25       | 65 | 1.99 (1.19–3.35) | 0.009  |
| G/-              |                     | 42    | 34       | 76 | 1.54 (0.96–2.48) | 0.088  |
| MC1R             | rs35414 (SLC45A2) |       |          |   |            |         |
| 0 C/C            |                     | 63    | 39       | 102| 1          | REF     |
| T/-              |                     | 95    | 133      | 228| 0.44 (0.27–0.71) | 0.001  |
| 1 C/C            |                     | 71    | 39       | 110| 1.13 (0.65–1.97) | 0.78   |
| T/-              |                     | 119   | 114      | 233| 0.65 (0.40–1.04) | 0.08   |
| 2/+ C/C          |                     | 45    | 6        | 51 | 4.64 (1.85–11.58) | 0.001  |
| T/-              |                     | 64    | 18       | 82 | 2.20 (1.14–4.23) | 0.02   |

OR, odds ratio per minor allele; CI, Confidence interval; REF, Reference value. Bold indicates statistically significant results.

doi:10.1371/journal.pone.0019271.t002
SNPs in that gene: rs16891982, rs35391 and rs28777. This last study concludes that the two noncoding SNPs, rs35391 and rs20777, are in LD with each other and are not significant melanoma risk predictors in a multivariate logistic regression models after adjusting for rs16891902 (p = 0.37). They confirm that rs16891902 is the SNP most strongly associated with melanoma risk in their population. These three SNPs are placed in the middle region of the SLCA5A2 gene, a segment of the gene that, according to HapMap data, does not belong to any block structure (probably due to their low minor allele frequencies in the Caucasian population where they were genotyped) (Figure S1).

The results obtained in this study support the protective role of SLCA5A2 and propose two novel intronic SNPs associated with MM predisposition. Both of these SNPs, rs35414 and rs35415, are located inside intron 1 of the SLCA5A2 gene, rs35415 (p-value = 0.0004 in phase I) was selected as the tag of the LD block located at the 5’ end of the gene, while rs35414, studied in phase I and validated in phase II (global p-value = 0.0001), is located in a region without apparent LD block structure (Figure S1). However, both SNPs (rs35414 and rs35415) are in strong linkage disequilibrium with each other (R² = 0.95) (Figure S1). Both constitute the second most common haplotype of the gene (43%), also conferring protection against melanoma (p-value = 0.0001). Thus, the association of this 5’ end region to MM predisposition suggests a putative involvement of unknown functional variants, in LD with these SNPs, involving regulatory elements in the promoter region of the SLCA5A2 gene.

Furthermore, the protective role of the rs35414 variant in SLCA5A2 is reinforced due to its capability to modulate the MM risk conferred by the MC1R locus.

Although no additional SNPs were replicated in the second phase of the study, three of them had statistical significance when the entire data collection was taken as a whole. Therefore, we consider them as quite relevant for further validations in other populations.

SLV (MIM# 155550) melanosomal matrix protein represents a melanoma specific antigen recognized by tumour infiltrating cytotoxic T lymphocytes [37]. It is also known as PMEL17, GP100 or ME20 [38] and it is crucial for proper formation and maturation of melanosomes. In stage II melanomas, processed SIVL protein aggregates to form fibrils, to which presumably the eumelanin pigment is attached [39]. It was found to be orthologous to the mouse silver locus. In this study, SNP rs2069398 was selected in order to represent the 5’ end of the SILV gene. Interestingly, the SILV locus is flanked quite closely on each side by CDK2 and D6GK at distances of 829 and 193bp, respectively, placed head to head with SILV/CDK2 in such a way as to allow sharing or overlapping promoter elements [40], rs2069398 is located in exon1 of the CDK2 gene, resulting in the synonymous polymorphism c.814G>A, p.Glu28Glu. The significance of this gene arrangement and the putative functionality of this SNP are yet to be tested.

The human tyrosinase gene (TTR, MIM# 606933) is another melanosomal membrane-bound enzyme that catalyzes the first two rate-limiting steps in the melanin biosynthesis pathway [41]. Mutations in the TTR gene cause the most severe form of oculocutaneous albinism OCA1 (TTR, MIM 606933, OCA1, MIM 203100) [42]. MM associated SNP rs17793678 is located in intron 1 and was selected as the tag for one of the five most frequent haplotypes formed at the promoter LD block in this gene (19 kb). Interestingly, TTR has previously been associated with melanoma in GWAS studies [18] performed in Caucasian populations other than our South European sample.

Finally, the ADAMTS20 protein (Δ disintegrin-like and metalloprotease domain with thrombospondin type-1 motifs, MIM# 611681) is a member of a family of secreted metallopro-
Paz University Hospital (Madrid), Ramon y Cajal University Hospital (Madrid), Castellon Province Hospital (Castellon), Cruces University Public Hospital (Barakaldo) and Basurto University Public Hospital (Bilbao). Similarly, 507 cancer-free controls were recruited from the Madril College of Lawyers, Gregorio Marañon Hospital, Castellon Province Hospital and the University of the Basque Country.

A standardized questionnaire was used to collect information on pigmentation characteristics (eye colour, hair colour, skin colour, number of naevi and presence of solar lentigines), the presence of childhood sunburns, Fitzpatrick's skin type classification (see Table S3), and personal and family history of cancer.

**Validation Phase II.** A second phase of the study, consisting of an independent validation series, was composed of 624 non-related sporadic MM cases obtained from the Departments of Dermatology of Instituto Valenciano de Oncología (Valencia) and Hospital Dr. Negrin from Las Palmas (Gran Canaria), Spain. A total of 789 cancer-free controls from the same two institutions were recruited. All subjects came from the geographical regions covered by the hospitals involved in the study. A recent work by Laayouni and cols. demonstrates lack of genetic heterogeneity covered by the hospitals involved in the study. A recent work by Laayouni and cols. demonstrates lack of genetic heterogeneity covered by the Basque country, by genome-wide single nucleotide polymorphism (SNP) array [46]. Sample distribution is listed in Table 3 (a+b).

Genomic DNA from cases and controls was isolated from peripheral blood lymphocytes and diluted to a final solution of 50 ng/μl. For the control subjects, this was done using the MagNA Pure LC Instrument according to the manufacturer’s protocol (Roche Applied Science, Mannheim, Germany) or the DNAzol procedure (Invitrogen, Eugene, OR, USA). The traditional saline method was used for MM cases. Quality control was performed for all samples before processing them on the Illumina arrays. DNA concentration was quantified in samples prior to genotyping by using Quant-IT PicoGreen dsDNA Reagent (Invitrogen, Eugene, OR, USA).

All subjects gave written informed consent and the study was approved by the Ethics Committee of Gregorio Marañon Hospital and University Clinic Hospital.

**Gene and SNP Selection**

Previous literature, information of public databases and information based on expression arrays [47] were used to perform gene selection in our candidate gene approach study. Genes were classified using Gene Ontology categories [48] with the help of the DAVID programmes [49]. Finally, 65 gene regions were included in the study (final list of genes available in Table S6). They covered a broad range of biological processes. Nevertheless, the most overrepresented categories were pigmentation GO:0033059 (11 genes, p-value = 2.13×10⁻¹⁰) and cellular pigmentation GO:0033058 (12 genes, p-value = 5.77×10⁻⁹). Another overrepresented category was membrane-bounded vesicle GO:001988 (12 genes, p-value = 1.39×10⁻¹¹), that includes genes coding for proteins located in the melanosome membrane (specialized lysosome implicated in melanin transport). Thus, their functions are related to pigmentation.

Our group had already analyzed exonic and putative functional SNPs in 15 genes associated with pigmentation syndromes or associated to defects in mice pigmentation [50]. However, in the current study, selected genes were analyzed using tag-SNPs ranging from the hypothetical promoter area (approximately 10 kb upstream) until approximately 5 kb downstream of the gene. SNP codes, locations, and frequencies were obtained from the NCBI (www.ncbi.nlm.nih.gov/SNP), HapMap (www.hapmap.org).

### Table 3. Sample distribution along discovery (phase I) and validation (phase II) sets.*

| Discovery Group (Phase I) | Institution Origin       | Cases (N = 590) | Controls (N = 507) |
|---------------------------|---------------------------|----------------|-------------------|
| n (%)                     | n (%)                     |
| CM                        | Gregorio Marañon Hospital | 155 (26.27)    | 27 (5.33)         |
|                           | Ramon y Cajal Hospital    | 120 (20.34)    | 0 (0.00)          |
|                           | La Paz Hospital           | 72 (12.2)      | 0 (0.00)          |
|                           | Madrid College of Lawyers| 0 (0.00)       | 218 (43.00)       |
| Sub-Total                 |                           | **347 (58.81)**| **245 (48.32)**   |
| CS                        | Castellon Province Hospital| 110 (18.64)    | 104 (20.51)       |
| Sub-Total                 |                           | **110 (18.64)**| **104 (20.51)**   |
| PV                        | Basurto Hospital          | 110 (18.64)    | 0 (0.00)          |
|                           | Cruces Hospital           | 23 (3.90)      | 0 (0.00)          |
|                           | University of the Basque Country| 0 (0.00)     | 158 (31.16)       |
| Sub-Total                 |                           | **133 (22.54)**| **158 (31.16)**   |

| Validation Group (Phase II) | Institution Origin       | Cases (N = 624) | Controls (N = 507) |
|-----------------------------|---------------------------|----------------|-------------------|
| n (%)                       | n (%)                     |
| Va                          | Instituto Valenciano Oncología | 412 (66.02)    | 558 (70.72)       |
| LP                          | Dr. Negrin Hospital        | 212 (33.97)    | 231 (29.27)       |

CM (Comunidad Madrid); CS (Castellon); PV (País Vasco); Va (Valencia); LP (Las Palmas de Gran Canaria).

*Total Discovery and validation sets were formed by 1214 Melanomas and 1296 control samples.

doi:10.1371/journal.pone.0019271.t003
org) and Illumina databases. Finally, 384 tag-SNPs were chosen to infer Linkage Disequilibrium (LD) blocks according to the HapMap project. To ensure a high genotyping success rate, a minor allele frequency threshold of 0.05 in the HapMap CEU population and an 'Illumina score' of not less than 0.6 (as recommended by the manufacturer) were established in the SNP selection process.

**SNP Genotyping**

SNPs were genotyped using the GoldenGate Genotyping Assay system according to the manufacturer's protocol (Illumina, San Diego, CA, USA). Genotyping was carried out using 350 nanograms of DNA per reaction. Genotyping specificity was assessed by including three DNA duplicates (two intra-assays and one inter-assay) and a negative control in each 96-well plate genotyped, yielding 100% consistent replication results. In addition, cases and control samples were always included in the same run. Genotypes were called using the proprietary software supplied by Illumina (BeadStudio, version 3.1.3).

Validation set genotyping was carried out using the TaqMan platform according to the manufacturer's protocol (Applied Biosystems, Foster City, CA, USA). For this validation, the six selected SNPs were analyzed using Taqman® SNP Genotyping Assays TTR (NM_000372.4) rs17793678, C_34306017_10; KIT (NM_000222.2) rs13135792, C_5288591_10; SLC45A2 (NM_016180.3) rs35414, C_2290581_10; SLY/CDK2 (NM_006928.3) rs2069398, C_15793372_10; ADAMTS20 (NM_025003.3) rs1510521, C_7519176_10 and Silv/CDK2 (NM_006928.3) rs1510521. Fifteen nanograms of DNA were used for the genotyping reactions. The genotype of each sample was automatically determined by measuring allele-specific final fluorescence in an ABI Prism 7900HT Detection System, using SDS 2.3 software for allele discrimination (Applied Biosystems, Foster City, CA, USA). As a quality control measure, at least two sample duplicates and a non-template sample per 96-well plate were included. Genotypes were scored by two different personnel in the laboratory. A concordance rate of 100% was obtained for all the SNPs tested.

**Haplotype analysis**

Haplotype information was obtained from the HapMap database (www.hapmap.org), using available data from the SLC45A2 gene (Chromosome 5; 33,975,000–34,025,000; version 28).

**Statistical Analysis**

Quality control processes and allelic and genotypic association tests were performed using the SNPassot package in discovery phase I (www.snpassot.com). Analyses performed in the validation set were conducted using SPSS v17.

For all polymorphisms studied, Fisher’s exact test was used both to test for deviations from Hardy-Weinberg equilibrium (HWE) among controls and to compare allele counts between cases and controls. Correction for multiple testing was carried out using the Bonferroni method. Genotype-related odds ratios, their corresponding 95% confidence intervals and associated p-values were estimated via unconditional logistic regression. Multivariate logistic regression was also applied, including age (categorical: <30, 30–39, 40–49, 50–59, 60–69, 70–79, ≥80), sex (male, female), hair colour (brown/black, blond/red), skin colour (fair, brown), lentigines (yes, no) and childhood sunburn (yes, no) as covariates. Associations between the genotyped pigmentation genes and various pigmentation characteristics and sun sensibility were assessed via logistic regression. This was done for cases and controls combined, with eye colour (blue/green versus brown), hair colour (brown/black versus blond/red), skin colour (fair versus brown), number of naevi (≥25 versus <25), presence of lentigines (yes versus no) and childhood sunburn (yes versus no) as the outcome variables.

A Bonferroni-adjusted nominal p-value threshold of 0.00015 was used to account for multiple testing, based on 341 effective independent marker loci (NP) among 363 SNPs studied. NP was calculated by applying the web-based programme SNPSpD [51] to SNPs on individual chromosomes (http://gump.qimr.edu.au/general/daleN/SNPSpD/). Fisher’s exact test had been used to account for differences in allele frequencies between HapMap CEU data and Spanish population data.

To study combinations of protective and risk genotypes, we used a 2×2 contingency table and a t-student test between SLC45A2 and SLY (rs35414 and rs2069398 respectively), between TTR and ADAMTS20 (rs17793678 and rs1510521 respectively) and between previous published results of MC1R (0, 1 or 2 variants) [22] and SLC45A2 (rs35414). Haplotype analysis was performed using the SNPSpD programme available at: http://bioinfo.iconcologia.net/index.php?module=Snpsstats.

**Supporting Information**

Figure S1 1D map of the SLC45A2 gene and tags selected in the study. (DOC)
Table S1 List of 363 successfully genotyped SNPs, Spanish MAF, HapMap_CEU MAF, and HWE p-value. (DOC)
Table S2 List of SNPs associated with Malignant Melanoma with p-value<0.05. (DOC)
Table S3 Association between SNPs and phenotypic characteristics. (DOC)
Table S4 Haplotype analysis of melanoma-associated variants previously reported in SLC45A2, including the candidate polymorphism detected in this study (rs35414). (DOC)
Table S5 Classification of the Spanish samples [phase I] by age and sex. (DOC)
Table S6 General information about genes, chromosomal location, SNPs per gene, associated disease, protein encoded and function in pigmentation. (DOC)

**Acknowledgments**

We thank the Madrileño College of Lawyers and all the participants from all the contributing Hospitals. We thank Tais Moreno and M. Rosario Alonso for their expert technical assistance with Illumina genotyping performed at the Spanish National Genotyping Centre (CeGen, Madrid). Genotyping with Taqman was performed at the Unidad Central de Investigación Médica (UCIM) of the Facultad de Medicina from the U. Valencia.

**Author Contributions**

Conceived and designed the experiments: LPF SA CM-C GR. Performed the experiments and statistical analysis: LPF MI-V MP-C G. Pita GR. Conceived of and are responsible for the selection and examination of the patients, obtained phenotypic and tumour information of all participants: MDB JAA MM CG-F BC MM G A. Pizarro MC GC RB-E EJ EL EB RL A. Pitarch G. Pitarch JMS-M FV-C GT-C GP-P JLD-P JG AS-D ImL CV.
Contributed reagents/materials/analysis tools: NI CDlR AA GP-Y YA-B AT-A AL JB. Contributed to the writing and editing of the manuscript: LPF MI-V SA CM-C GR. All authors revised the final version of the manuscript.

References

1. Saenz S, Conejo-Mir J, Cayuela A (2005) [Melanoma epidemiology in Spain]. Actas Dermosifiliogr 96: 411–418.
2. Bataille V (2003) Genetic epidemiology of melanoma. Eur J Cancer 39: 1341–1347.
3. Lin JY, Fisher DE (2000) Melanocyte biology and skin pigmentation. Nature 445: 843–850.
4. Miller AJ, Mihm MC, Jr. (2006) Melanoma. N Engl J Med 355: 55–65.
5. Newton Bishop JA, Bishop DT (2003) The genetics of susceptibility to cutaneous melanoma. Drugs Today (Barc) 41: 193–203.
6. Bishop JN, Harland M, Bishop DT (2006) The genetics of melanoma. Br J Hosp Med (Lond) 67: 299–304.
7. Mohrenweiser HW, Wilson DM, 3rd, Jones IM (2003) Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat Res 526: 93–125.
8. Fargnoli MC, Altobelli E, Keller G, Chimienti S, Holler H, et al. (2006) Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study. Melanoma Res 16: 175–182.
9. Fernandez L, Milne R, Bravo J, Lopez J, Aviles J, et al. (2007) MC1R: three novel variants identified in a malignant melanoma association study in the Spanish population. Carcinogenesis 28: 1659–1664.
10. Gerstebühl MR, Goldstein AM, Fargnoli MC, Peris K, Landi MT (2007) Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum Mutat 28: 495–505.
11. Matchard D, Verplack R, Mezani R, Gerhard B, Descamps V, et al. (2004) Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet 41: e13.
12. Valverde P, Healy E, Jackson I, Rees J, Thody AJ (1995) Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 11: 329–330.
13. Scherer D, Nagore E, Bermejo JL, Figl A, Botella-Estrada R, et al. (2009) Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol 130: 520–528.
14. Brown KM, Macgregor S, Montgomery GW, Craig DW, Zhao ZZ, et al. (2008) A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet 4: e1000074.
15. Sulen P, Guddbjartsson DF, Stacey SN, Helgason A, Rafnar T, et al. (2008) ASIP and TYR pigmentation variants associate with cutaneous and basal cell carcinoma. Nat Genet 40: 836–891.
16. Han J, Kraif P, Nan H, Guo Q, Chen C, et al. (2008) A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet 4: e1000074.
17. Soejima M, Tachida H, Ishida T, Sano A, Koda Y (2006) Evidence for recent ancestry. Trends Genet 20: 327–332.
18. Gudbjartsson DF, Stacey SN, Goldstein AM, Fargnoli MC, Peris K, et al. (2007) Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum Mutat 28: 495–505.
19. Soejima M, Tachida H, Ishida T, Sano A, Koda Y (2006) Evidence for recent ancestry. Trends Genet 20: 327–332.
20. Sulem P, Gudbjartsson DF, Stacey SN, Helgason A, Rafnar T, et al. (2008) Genetic determinants of hair, eye and skin pigmentation in Europeans. Nat Genet 39: 1443–1452.
21. Cawthon RM, Carey VJ, Sherriff SA, Michel R, Horsley V, et al. (2006) New variants identified in a malignant melanoma association study in the Spanish population. Carcinogenesis 28: 1659–1664.
22. Sulem P, Gudbjartsson DF, Stacey SN, Helgason A, Rafnar T, et al. (2008) Genetic determinants of hair, eye and skin pigmentation in Europeans. Nat Genet 39: 1443–1452.
23. Gueoq M, Bertrand E, Combadieres C, Rodero M, Desave P, et al. (2000) Variants of the MATP/SLC45A2 gene are protective for melanoma in the French population. Hum Mutat 29: 1161–1167.
24. Duffy DL, Zhao ZZ, Sturm RA, Hayward NK, Martin NG, et al. (2010) Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol 130: 520–528.
25. Duffy DL, Ibs MM, Glass D, Zhu G, Barrett JH, et al. (2010) IRF4 variants have age-specific effects on nevus count and predispose to melanoma. Am J Hum Genet 87: 411–418.
26. Sturm RA, Frudakis TN (2004) Eye colour: portals into pigmentation genes and ancestry. Trends Genet 20: 327–332.